Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search


Modag is a Wendelsheim-based company developing molecular diagnostics and treatments for neurodegenerative diseases founded in 2013.

MODAG GmbH - Overview

MODAG focuses on research and development of therapeutics and diagnostics for neurodegenerative diseases. It is a privately held company located at the Hochtechnologiepark Wendelsheim, Germany with additional Research & Development facilities in Munich and Göttingen. MODAG’s innovative approach offers a unique combination of early diagnosis and targeted disease-modifying therapies for severe neurological disorders.

MODAG´s collaborations with top-tier US and European research institutions, combined with the interdisciplinary research and development expertise of the founder´s and the management team, provide ideal conditions for the accelerated implementation into clinical applications. Built upon an extensive portfolio of patented active compounds, MODAG is developing a new oligomer modulator for Multiple System Atrophy (MSA) and other synucleinopathies such as Parkinson´s disease (PD) with the potential to deliver novel disease-modifying, first-in-class drugs with the potential to halt progression.

Company History

In a cooperation with the teams of Prof. Dr. Armin Giese at the LMU Munich and Prof. Dr. Dr. h.c. Christian Griesinger at the Max Planck Institute for Biophysical Chemistry Göttingen, a new class of oligomer modulators was identified with an innovative screening platform based on single particle fluorescence technology (SIFT).

This drug development program led to the identification of anle138b and more than 250 analogs, which are protected by several patents. In addition to the non-dilutive financing through grants, MODAG successfully completed a first round of seed funding in 2013 with the participation of “Bayerische Patentallianz GmbH”, “Max Planck Innovation” and the founding partners Prof. Dr. Armin Giese, Prof. Dr. Christian Griesinger, Dr. Marcus Kostka and Dr. Torsten Matthias as the main investor of this seed financing.

Following the successful completion of the anle138b preclinical development program and the development of the associated diagnostic tools, MODAG has secured Series A financing in 2019 and is currently advancing lead program anle138b into Phase 1 clinical trial.


Funding rounds


Further Resources

Golden logo
By using this site, you agree to our Terms & Conditions.